What We Know About Three-Parent In VitroFertilization
By Jessica Cussins,
RH Reality Check
| 03. 13. 2014
The Food and Drug Administration (FDA) held a public meeting in late February to consider experimental new techniques that would modify human eggs or embryos in an attempt to allow women with severely mutated mitochondrial DNA to have a child that would not inherit the disorders that can be caused by those mutations. The meeting also considered the use of similar techniques for cases of infertility.
The numerous concerns raised during the two-day meeting made it clear that there are still gaping holes in the data and countless issues to work through. But a strange thing happened: Many people from across the political and professional spectrum unexpectedly found common ground. Apparently most people can agree that anyone who hopes to wield that kind of power carries the burden of proof that their technique works, that it would be safe, and that there are no better alternatives.
As of right now, the case for these new technologies does not look very strong.
The procedures, of which there are a couple variations, have been called everything from “mitochondrial manipulation” to “three-parent IVF...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...